XRAY Stock Forecast 2025-2026
Distance to XRAY Price Targets
XRAY Price Momentum
10 Quality Stocks Worth Considering Now
Researching DENTSPLY SIRONA (XRAY) after the drop? Our ex-Goldman Sachs analyst reveals if it made our list of 10 oversold quality stocks with strong growth potential.
Get our FREE market selloff report + exclusive analysis on XRAY and similar high-potential opportunities.
Latest XRAY Stock Price Targets & Analyst Predictions
Based on our analysis of 23 Wall Street analysts, XRAY has a neutral consensus with a median price target of $19.00 (ranging from $14.00 to $27.00). The overall analyst rating is Buy (6.7/10). Currently trading at $12.83, the median forecast implies a 48.1% upside. This outlook is supported by 4 Buy, 13 Hold, and 0 Sell ratings.
The most optimistic forecast comes from Kevin Caliendo at UBS, projecting a 110.4% upside.
Please note that analyst price targets are forward-looking estimates subject to substantial market, economic, and company-specific risks. Past performance does not guarantee future results, and actual stock performance may materially differ from these projections. Investors should conduct their own due diligence and consider their investment objectives and risk tolerance before making investment decisions.
XRAY Analyst Ratings
XRAY Price Target Range
Latest XRAY Stock Forecasts by Analyst
These are the latest 20 analyst ratings and price targets for XRAY.
| Date | Firm | Analyst | Rating | Change | Price Target |
|---|---|---|---|---|---|
| Mar 13, 2025 | Needham | David Saxon | Hold | Downgrade | $0.00 |
| Mar 13, 2025 | Mizuho | Steven Valiquette | Neutral | Maintains | $18.00 |
| Feb 28, 2025 | Needham | David Saxon | Buy | Maintains | $23.00 |
| Feb 28, 2025 | Baird | Jeffrey Johnson | Neutral | Maintains | $20.00 |
| Feb 28, 2025 | Wells Fargo | Vik Chopra | Equal-Weight | Maintains | $19.00 |
| Feb 28, 2025 | Barrington Research | Michael Petusky | Outperform | Maintains | $20.00 |
| Feb 14, 2025 | Wells Fargo | Vik Chopra | Equal-Weight | Initiates | $20.00 |
| Feb 11, 2025 | Needham | David Saxon | Buy | Reiterates | $25.00 |
| Jan 30, 2025 | Needham | David Saxon | Buy | Maintains | $25.00 |
| Jan 23, 2025 | Jefferies | Glen Santangelo | Hold | Downgrade | $20.00 |
| Jan 7, 2025 | Evercore ISI Group | Elizabeth Anderson | In-Line | Downgrade | $20.00 |
| Dec 17, 2024 | Morgan Stanley | Erin Wright | Overweight | Maintains | $23.00 |
| Dec 4, 2024 | Mizuho | Steven Valiquette | Neutral | Initiates | $21.00 |
| Dec 3, 2024 | UBS | Kevin Caliendo | Buy | Maintains | $27.00 |
| Nov 8, 2024 | Baird | Jeffrey Johnson | Neutral | Maintains | $24.00 |
| Nov 8, 2024 | Barrington Research | Michael Petusky | Outperform | Maintains | $24.00 |
| Nov 7, 2024 | Leerink Partners | Michael Cherny | Market Perform | Downgrade | $0.00 |
| Oct 28, 2024 | Needham | David Saxon | Buy | Maintains | $29.00 |
| Oct 8, 2024 | Evercore ISI Group | Elizabeth Anderson | Outperform | Maintains | $27.00 |
| Sep 20, 2024 | Barrington Research | Michael Petusky | Outperform | Maintains | $36.00 |
Dentsply Sirona Inc. (XRAY) Competitors
The following stocks are similar to DENTSPLY SIRONA based on their market capitalization and industry sector. These similar stocks potentially provide investors with alternative investment opportunities within the same market segment.
Dentsply Sirona Inc. (XRAY) Financial Data
Dentsply Sirona Inc. has a market capitalization of $2.56B with a P/E ratio of -2.9x. The company generates $3.79B in trailing twelve-month revenue with a -24.0% profit margin.
Revenue growth is -10.6% quarter-over-quarter, while maintaining an operating margin of +4.0% and return on equity of -34.8%.
Valuation Metrics
Growth & Margins
Financial Health
Get All 10 Quality Stocks For This Market Selloff
Still researching investments after the market drop? Our ex-Goldman Sachs analyst has already identified the 10 highest-quality oversold stocks with strong fundamentals and upside potential.
Why spend hours researching when we've already done the work? Get instant access to our complete market selloff analysis.
Dentsply Sirona Inc. (XRAY) Business Model
About Dentsply Sirona Inc.
Leading provider of dental solutions and technologies.
Dentsply Sirona generates revenue by designing, manufacturing, and marketing a wide range of dental products and technologies. Their offerings include consumables, equipment, and digital tools aimed at dental practitioners, laboratories, and clinics, which allows them to cater to various segments within the dental industry.
Founded in 1899 and headquartered in Charlotte, North Carolina, the company has a strong global presence and is committed to innovation, improving efficiencies in dental practices, and enhancing patient care. Their focus on high-quality and sustainable solutions significantly contributes to advancing oral health standards.
Company Information
Sector
Healthcare
Industry
Medical Instruments & Supplies
Employees
14,000
CEO
Mr. Simon D. Campion
Country
United States
IPO Year
1991
Website
www.dentsplysirona.comDentsply Sirona Inc. (XRAY) Latest News & Analysis
Bronstein, Gewirtz & Grossman, LLC is investigating potential claims for Dentsply Sirona Inc. (NASDAQ:XRAY) investors who purchased before May 6, 2021. More info is available at bgandg.com/XRAY.
The investigation into Dentsply Sirona may indicate potential legal issues or financial discrepancies, affecting investor confidence and the company's stock performance.
Bronstein, Gewirtz & Grossman, LLC is investigating potential claims for investors of Dentsply Sirona Inc. (NASDAQ:XRAY) who purchased shares before May 6, 2021.
The investigation indicates potential legal issues for Dentsply, which could affect its stock value and investor confidence, prompting scrutiny over the company's financial health and management practices.
XRAY is experiencing growth due to a strong product portfolio, but faces challenges from weakened global demand and macroeconomic factors.
XRAY’s strong product portfolio suggests growth potential, but weakened global demand may hinder overall performance, impacting revenue and stock valuations.
Four stocks from the Dental Supplies industry with potential for investment growth are CAH, MMSI, XRAY, and CNMD.
The mention of specific stocks in the Dental Supplies industry suggests potential growth opportunities, signaling to investors which companies may offer promising returns.
Bronstein, Gewirtz & Grossman, LLC is investigating potential claims for Dentsply Sirona Inc. (NASDAQ:XRAY) investors who bought shares before May 6, 2021.
The investigation into Dentsply Sirona may signal potential legal issues or financial irregularities, impacting stock performance and investor confidence.
Dentsply Sirona (Nasdaq: XRAY) will host an investor conference call and webcast on May 8, 2025, at 8:30 am ET to discuss Q1 financial results. Presentation available online.
Dentsply Sirona's upcoming investor call on May 8 will provide crucial insights into its Q1 financial performance, influencing stock valuation and investor sentiment.
Frequently Asked Questions About XRAY Stock
What is Dentsply Sirona Inc.'s (XRAY) stock forecast for 2025?
Based on our analysis of 23 Wall Street analysts, Dentsply Sirona Inc. (XRAY) has a median price target of $19.00. The highest price target is $27.00 and the lowest is $14.00.
Is XRAY stock a good investment in 2025?
According to current analyst ratings, XRAY has 4 Buy ratings, 13 Hold ratings, and 0 Sell ratings. The stock is currently trading at $12.83. Always conduct your own research and consider your investment goals before making investment decisions.
What is the long-term price prediction for XRAY stock?
Wall Street analysts predict XRAY stock could reach $19.00 in the next 12 months. This represents a 48.1% increase from the current price of $12.83. Please note that this is a projection by Wall Street analysts and not a guarantee.
What is Dentsply Sirona Inc.'s business model?
Dentsply Sirona generates revenue by designing, manufacturing, and marketing a wide range of dental products and technologies. Their offerings include consumables, equipment, and digital tools aimed at dental practitioners, laboratories, and clinics, which allows them to cater to various segments within the dental industry.
What is the highest forecasted price for XRAY Dentsply Sirona Inc.?
The highest price target for XRAY is $27.00 from Kevin Caliendo at UBS, which represents a 110.4% increase from the current price of $12.83.
What is the lowest forecasted price for XRAY Dentsply Sirona Inc.?
The lowest price target for XRAY is $14.00 from at , which represents a 9.1% increase from the current price of $12.83.
What is the overall XRAY consensus from analysts for Dentsply Sirona Inc.?
The overall analyst consensus for XRAY is neutral. Out of 23 Wall Street analysts, 4 rate it as Buy, 13 as Hold, and 0 as Sell, with a median price target of $19.00.
How accurate are XRAY stock price projections?
Stock price projections, including those for Dentsply Sirona Inc., are based on various factors including financial models, market conditions, and analyst forecasts. While these predictions provide valuable insights, they should be considered alongside your own research and risk tolerance.
Important Disclaimer
The information provided by Ticker Nerd is for educational and informational purposes only. It should not be considered financial or investment advice. Past performance is not indicative of future results. Always conduct your own research and consult with a qualified financial advisor before making any investment decisions. Analyst ratings and price forecasts are sourced from Wall St analysts and other experts. These projections are speculative and do not guarantee future stock performance.